Rituximab and Bendamustine (BR) Compared with Rituximab, Bendamustine, and Cytarabine (R-BAC) in Previously Untreated Elderly Patients with Mantle Cell Lymphoma
Authors:
- Giulia BegaGBGiulia Bega
- Jacopo OlivieriJOJacopo Olivieri
- Marcello RivaMRMarcello Riva
- Greta ScapinelloGSGreta Scapinello
- Rossella PaoliniRPRossella Paolini
- Silvia FinottoSFSilvia Finotto
- Roberto SartoriRSRoberto Sartori
- Elisa LucchiniELElisa Lucchini
- Gianmarco GuandaliniGGGianmarco Guandalini
- Davide FacchinelliDFDavide Facchinelli
- Maria Chiara TisiMTMaria Chiara Tisi
- Marco BassoMBMarco Basso
Open Access
Abstract
Background: Rituximab plus bendamustine (BR), and rituximab, bendamustine, and cytarabine (R-BAC) are well-known induction therapies in elderly patients with mantle cell lymphoma (MCL), according to clinical guidelines. However, a direct comparison between the two regimens has never been performed. Methods: In this multicentre retrospective study, we compared the outcome of patients with newly diagnosed MCL, treated with BR or R-BAC. Primary endpoint was 2-year progression-free survival (PFS). Inclusion bias was assessed using a propensity score stratified by gender, age, MCL morphology, and MIPI score. Results: After adjusting by propensity score, we identified 156 patients (53 BR, 103 R-BAC) with median age of 72 (53–90). Median follow-up was 46 months (range 12–133). R-BAC was administered in a 2-day schedule or with attenuated dose in 51% of patients. Patients treated with R-BAC achieved CR in 91% of cases, as compared with 60% for BR (p < 0.0001). The 2-year PFS was 87 ± 3% and 64 ± 7% for R-BAC and BR, respectively (p = 0.001). In terms of toxicity, R-BAC was associated with significantly more pronounced grade 3–4 thrombocytopenia than BR (50% vs. 17%). Conclusions: This study indicates that R-BAC, even when administered with judiciously attenuated doses, is associated with significantly prolonged 2-year PFS than BR in elderly patients with previously untreated MCL.Keywords
This publication has 16 references indexed in Scilit:
- Time to progression of mantle cell lymphoma after high‐dose cytarabine‐based regimens defines patients risk for deathBritish Journal of Haematology, 2018
- Newly diagnosed and relapsed mantle cell lymphoma: ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-upAnnals of Oncology, 2017
- Rituximab, bendamustine, and low-dose cytarabine as induction therapy in elderly patients with mantle cell lymphoma: a multicentre, phase 2 trial from Fondazione Italiana LinfomiThe Lancet Haematology, 2017
- The 2016 revision of the World Health Organization classification of lymphoid neoplasmsBlood, 2016
- Ibrutinib in mantle cell lymphoma patients: glass half full? Evidence and opinionTherapeutic Advances in Hematology, 2015
- Randomized trial of bendamustine-rituximab or R-CHOP/R-CVP in first-line treatment of indolent NHL or MCL: the BRIGHT studyBlood, 2014
- Bendamustine plus rituximab versus CHOP plus rituximab as first-line treatment for patients with indolent and mantle-cell lymphomas: an open-label, multicentre, randomised, phase 3 non-inferiority trialThe Lancet, 2013
- Treatment of Older Patients with Mantle-Cell LymphomaNew England Journal of Medicine, 2012
- Improvement of Overall Survival in Advanced Stage Mantle Cell LymphomaJournal of Clinical Oncology, 2009
- Staging and Evaluation of the Patient with LymphomaHematology/Oncology Clinics of North America, 2008